SNS 101
Alternative Names: SNS-101 - Sensei Biotherapeutics; SNS-VISTALatest Information Update: 22 Nov 2024
Price :
$50 *
At a glance
- Originator Sensei Biotherapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; VISTA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 14 Nov 2024 Sensei Biotherapeutics plans phase II trial in Cancer
- 31 May 2024 Updated efficacy and adverse event data from a phase I/II trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 23 May 2024 Updated efficacy and adverse events data from a phase I/II trial in Solid tumours released by Sensei Biotherapeutics